SS-31 (elamipretide)

SS-31 (elamipretide) is a synthetic mitochondria-targeting peptide that the longevity field pays attention to because it protects the cell’s power plants — and it is now FDA-approved as Forzinity for a rare mitochondrial disease. For everyday anti-aging, though, the human evidence is early and mixed, not settled.

If you’re here, you probably ran into SS-31 in a longevity thread — pitched as a mitochondrial “anti-aging” peptide — and want to know whether the science backs the hype. The short version: SS-31 is further down the clinical road than almost any other compound in this corner of the site, which makes its story unusually concrete. It also means the honest gaps are specific, not hand-wavy.

What is SS-31 (elamipretide)?

SS-31 (elamipretide) is a lab-made peptide — a short chain of just four amino acids (D-Arg-Dmt-Lys-Phe-NH2) — designed to concentrate inside mitochondria, the tiny structures that generate almost all of a cell’s energy. It was invented in an academic lab (the “SS” stands for its inventors, Szeto and Schiller), and picked up a string of names along the way: MTP-131 and Bendavia during drug development, and finally Forzinity (elamipretide) as an approved medicine. It is small (molecular weight ≈ 639.8) and water-soluble, and it is given by injection. One thing to keep straight from the start: SS-31 the drug and “SS-31” the research-chemical powder are chemically the same molecule but are not the same regulated product — only the drug went through FDA review.

How does SS-31 work?

SS-31 works by parking itself in the inner membrane of the mitochondrion and binding a lipid there called cardiolipin — the surface the cell’s energy machinery (the electron transport chain) is mounted on. Think of an aging power plant with frayed wiring: energy leaks out as heat and sparks, and less electricity reaches the outlets. By stabilizing cardiolipin, SS-31 acts a bit like re-insulating that wiring, so studies report the machinery runs cleaner — more usable energy (ATP, the molecule cells run on) and fewer leaked reactive-oxygen byproducts (the “sparks” that damage cells over time) (mechanism research on PubMed). That is the whole reason SS-31 lands in the longevity conversation: failing mitochondria are one of the recognized hallmarks of aging, and SS-31 targets them directly. The honest caveat is that “protects mitochondria in a study” is a mechanism, not a promise that it slows human aging.

What does the research show?

SS-31 stands apart from most longevity peptides because it has been through the clinical wringer. A PubMed search returns hundreds of records — over 140 tagged as human research and more than a dozen randomized controlled trials — plus roughly 20 registered clinical studies (PubMed; ClinicalTrials.gov). The catch for a longevity reader: almost all of that testing was for specific diseases, not for slowing aging in healthy people. Here is the honest split, use by use.

Use	Best evidence so far	What it showed
Age-related muscle & mitochondrial energy (the longevity use)	Human (controlled), small early trials + a new one recruiting	Mixed and inconclusive so far; no proven anti-aging benefit
Barth syndrome (rare disease)	Human RCT — led to FDA approval	Approved as Forzinity; pivotal data was small and debated
Primary mitochondrial myopathy (broad)	Human RCT (Phase 3)	Did not meet its primary endpoint
Dry AMD (geographic atrophy)	Human RCT — Phase 3 ongoing	Still being tested; not established
Heart failure	Human RCT (Phase 2)	No clear benefit shown so far

For the longevity use specifically, SS-31 has been tested on skeletal-muscle function and mitochondrial energy in older adults in a Phase 2 study (NCT02245620), and a dedicated “Study of Healthy Aging and Physical Function With Elamipretide” began recruiting in late 2025 (NCT07275424). That is real human evidence — which is more than most anti-aging peptides can say — but it is small and mixed, so SS-31’s anti-aging case is still being written, not finished.

On the disease side, the story is two-sided, and we won’t sand off either edge. SS-31 (as elamipretide) earned FDA approval for Barth syndrome, a rare inherited mitochondrial disorder, under the brand Forzinity (Barth trial NCT03098797; a Phase 4 confirmatory study, NCT07531251, is now underway). But its biggest swing at broad mitochondrial disease — the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy — did not meet its primary endpoint (NCT03323749). SS-31 is also in a Phase 3 eye trial for dry age-related macular degeneration (ReNEW, NCT06373731) and has been tested in heart failure without a clear win yet. The pattern that matters for a longevity reader: SS-31 is a real, approved drug for one rare condition, and an open question for everything the biohacker crowd actually wants it for.

Is SS-31 safe? Side effects

SS-31’s safety is better understood than almost any other peptide on this site, for a simple reason: elamipretide was studied in thousands of patient-exposures and reviewed by the FDA before approval. Across its trials, the most commonly reported problem was injection-site reactions — redness, itching, or irritation where the shot goes in — which were usually mild (Forzinity label via DailyMed). That is a reassuring short-term picture. Two honest limits remain. First, that safety record was built in sick populations under medical supervision, not in healthy adults microdosing for longevity. Second, there is no long-term data on years of anti-aging use, because nobody has run that study. And the research-grade “SS-31” powder carries the usual research-chemical risks — quality control over its purity, dosing accuracy, and sterility is left entirely to whoever sells it, and it isn’t the FDA-reviewed product.

FDA & legal status (2026)

SS-31 (elamipretide) is FDA-approved — but only in a narrow lane. As of 2026, the FDA has approved elamipretide as the prescription drug Forzinity (NDA 215244, Stealth BioTherapeutics) for Barth syndrome, a rare inherited mitochondrial disorder (Drugs@FDA / DailyMed). It is not approved for anti-aging, “mitochondrial support,” athletic recovery, or general longevity. That gap is the crux of the whole page: the “SS-31” powder sold online for those purposes is an unapproved research chemical, legally separate from Forzinity even though it’s the same molecule. Regulatory status can move — approvals expand, labels change — so treat this as dated to 2026 and re-check the FDA record for anything newer.

How is SS-31 used and dosed?

In its clinical trials, SS-31 (elamipretide) was given as a daily subcutaneous injection — a shot into the fat just under the skin — often after being reconstituted from a freeze-dried powder (mixing the powder with sterile liquid to turn it back into an injectable solution). We’re describing how it was studied, not writing you a protocol: for the approved drug, the exact dose and schedule are set by the FDA label, not by us (Forzinity label). For anyone working out concentrations from a research-grade vial, the arithmetic of “how many units to draw” is exactly what our reconstitution & dosing calculator handles, and if you’re wondering whether SS-31 shares a syringe with other compounds, our mixing compatibility reference covers what’s commonly combined and where the honest answer is “not enough data.” Neither is a recommendation to use it — they’re reference tools.

SS-31 and the longevity landscape

SS-31 sits in the longevity & mitochondrial peptides cluster — the most speculative corner of the field, alongside compounds like MOTS-c, humanin, and Epitalon that target the machinery of aging itself. Within that landscape, SS-31 is the rare one with a real FDA approval behind it, which makes it a useful anchor for the whole category. The same longevity-and-recovery audience often looks at growth-hormone-axis compounds too — the FDA-approved tesamorelin, the muscle-preservation candidate follistatin, and the oral GH-secretagogue MK-677 — though those work on completely different pathways and shouldn’t be treated as interchangeable with a mitochondrial peptide.

Hype vs. reality

The biggest SS-31 claim floating around is that it “reverses aging” or “repairs your mitochondria.” Here’s the honest grading. That SS-31 stabilizes cardiolipin and improves mitochondrial energy output in lab and animal work is well-supported — but that’s a mechanism, not a proven human outcome. That SS-31 treats a specific mitochondrial disease is now true and FDA-backed, for Barth syndrome only. That SS-31 slows aging or extends healthspan in healthy people is the part everyone actually wants, and it remains a hypothesis with early, mixed human data — closer to “worth testing” than “proven.” The exciting, true thing is that the testing is happening, in people, right now.

Frequently asked questions

Does SS-31 actually work for anti-aging?

Not proven — yet. SS-31 has a strong mechanistic case (it protects mitochondria) and, unusually, real early human trials in older adults, but the anti-aging results so far are small and mixed. A dedicated healthy-aging trial only started recruiting in late 2025. We grade the longevity use Human (controlled) with a mixed verdict: promising and actively being tested, not settled.

Is SS-31 legal?

SS-31 is legal as an FDA-approved prescription drug — Forzinity (elamipretide) — but only for its approved use, Barth syndrome. The “SS-31” powder sold online for longevity is an unapproved research chemical, marketed “for research use only,” which is a liability label, not a safety guarantee.

Is SS-31 the same as elamipretide and Forzinity?

Yes — SS-31, elamipretide, MTP-131, and Bendavia are all names for the same molecule, and Forzinity is the FDA-approved brand of it. The difference that matters is regulatory, not chemical: Forzinity is a reviewed medicine, while research-grade “SS-31” powder is not.

How do people take SS-31?

In trials, SS-31 was given as a daily subcutaneous injection. That’s background on how it was studied, not a how-to — the approved drug’s dosing is defined by its FDA label and a prescriber, and community “anti-aging” dosing is not clinically validated.

Is SS-31 banned in sport?

SS-31’s anti-doping status isn’t clearly defined on the WADA Prohibited List by name as of 2026, and now that elamipretide is an approved drug the old “non-approved substance” catch-all doesn’t cleanly apply. That ambiguity is exactly why any athlete subject to testing should confirm with USADA or their anti-doping authority before assuming anything.

Who SS-31 is for — and who should wait

SS-31 draws in the longevity-minded self-researcher — the person who’s read that failing mitochondria drive aging and wants a compound that targets them directly. The honest framing: SS-31 is one of the very few peptides in this space with a real FDA approval and a solid short-term human safety record, which is a genuine point in its favor. But that approval is for a rare disease, its biggest broad trial missed, and the anti-aging benefit people actually want is still early and mixed. The strongest reason for optimism isn’t hype — it’s that the human trials are running now, not absent. Anyone expecting a proven age-reversal shot, or unwilling to accept that the longevity use is unapproved and under-tested, has every reason to watch the trials read out first.